Glycoform Ltd. aims to leverage the pioneering glyco-chemistry research of its Oxford University founders to develop targeted drug delivery systems and to improve the safety and efficacy of protein therapeutics, including monoclonal antibodies.
The firm hopes to take advantage of the way specific oligosaccharides, or sugar motifs, can affect the properties of the proteins they decorate. Its expertise in synthesizing these sugars and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?